Existing epidemiologic and clinical trial data suggest that the blood pressure in patients with hypertension at high risk for cardiovascular events because of coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, or heart failure should be reduced to ,140/90 mm Hg in patients younger than 80 years and the systolic blood pressure be reduced to 140-145 mm Hg if tolerated in patients aged 80 years and older. Studies from patients with coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, and heart failure will be discussed that support a blood pressure goal of ,140/90 mm Hg in patients younger than 80 years at high risk for cardiovascular events.
INTRODUCTION
Hypertension is a major risk factor for cardiovascular events. 1, 2 Hypertension is present in approximately 69% of patients with first myocardial infarction, 3 in approximately 77% of patients with first stroke, 3 in approximately 74% of patients with congestive heart failure, 3 and in 60% of patients with peripheral arterial disease. 4 This article discusses the optimal blood pressure goal in patients at high risk for cardiovascular events.
GUIDELINES
In the absence of randomized control data, the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure recommended that patients with diabetes mellitus or with chronic kidney disease should have their blood pressure lowered to ,130/80 mm Hg. 1 In the absence of randomized control data, the American Diabetes Association recommended that patients with diabetes mellitus and hypertension should have their blood pressure lowered to ,130/80 mm Hg. 5 In the absence of randomized control data, the National Kidney Foundation Kidney Disease Outcome Quality Initiative guidelines recommended that patients with chronic kidney disease and hypertension should have their blood pressure lowered to ,130/80 mm Hg. 6 In the absence of randomized control data, the American Heart Association 2007 guidelines recommended that patients with hypertension at high risk for coronary events such as those with coronary artery disease, a coronary artery risk equivalent, diabetes mellitus, chronic kidney disease, or a 10-year Framingham risk score $10% should have their blood pressure reduced to ,130/80 mm Hg. 7 These guidelines also recommended that patients with hypertension and left ventricular dysfunction should have their blood pressure reduced to ,120/80 mm Hg. data and that the systolic blood pressure should be lowered to ,140 mm Hg in these patients. 8 The American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly recommended that the blood pressure should be lowered to ,140/90 mm Hg in adults younger than 80 years at high risk for cardiovascular events. 2 On the basis of data from the Hypertension in the Very Elderly trial, 9 these guidelines recommended that the systolic blood pressure should be reduced to 140-145 mm Hg if tolerated in adults aged 80 years and older. The author concurs with these guidelines. 2, [10] [11] [12] [13] [14] [15] The following studies discuss the reasons for the recommendations.
STUDIES OF OPTIMAL BLOOD PRESSURE IN HIGH-RISK PATIENTS
The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial enrolled 4162 patients with an acute coronary syndrome (acute myocardial infarction with or without ST-segment elevation or high-risk unstable angina pectoris), 17% with diabetes mellitus (Table 1) . 16 At 24-month mean follow-up, the lowest cardiovascular events rates occurred with a systolic blood pressure between 130 and 140 mm Hg and a diastolic blood pressure between 80 and 90 mm Hg with a nadir of 136/85 mm Hg. 16 The investigators suggested that a blood pressure ,110/70 mm Hg might be dangerous for patients with an acute coronary syndrome.
An observational subgroup analysis was performed in 6400 of the 22,576 patients enrolled in the International Verapamil SR-Trandolapril Study (Table 1) . 17 These patients had diabetes mellitus and coronary artery disease. These patients were categorized as having tight control of their blood pressure if they could maintain their systolic blood pressure below 130 mm Hg and their diastolic blood pressure below 85 mm Hg, as usual control if they could maintain their systolic blood pressure between 130 and 139 mm Hg, and as uncontrolled if their systolic blood pressure was 140 mm Hg or higher. During 16,893 patient-years of follow-up, a cardiovascular event rate of 12.6% occurred in patients with usual control of blood pressure versus 19.8% in patients with uncontrolled hypertension [adjusted hazard ratio 5 1.46; 95% confidence interval (CI): 1.25-1.71; P ,0.001]. 17 The incidence of cardiovascular events was 12.6% in patients with usual control of blood pressure versus 12.7% in patients with tight control of blood pressure (P not significant). The all-cause mortality rate was 11.0% with tight control of blood pressure versus 10.2% with usual control of blood pressure (P 5 0.06). When extended follow-up to 5 years following the close of International Verapamil SR-Trandolapril Study was included, the all-cause mortality rate was 22.8% with tight control of blood pressure versus 21.8% with usual control of blood pressure (adjusted hazard ratio 5 1.15; 95% CI: 1.01-1.32; P 5 0.04). 17 The Action to Control Cardiovascular Risk in Diabetes blood pressure trial randomized 4733 patients with type 2 diabetes mellitus to intensive blood pressure control with a target systolic blood pressure of ,120 mm Hg or to standard blood pressure control with a target systolic blood pressure ,140 mm Hg (Table 1) . 18 The primary composite outcome was nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. Mean follow-up was 4.7 years. After 1 year, the mean systolic blood pressure was 119.3 mm Hg in the intensive blood pressure control group versus 133.5 mm Hg in the standard blood pressure control group. The annual rate of the primary outcome was 1.87% in the intensive blood pressure control group versus 2.09% in the standard blood pressure control group (P not significant). 18 The annual rate of death from any cause was 1.28% in the intensive blood pressure control group versus 1.19% in the standard blood pressure control group (P not significant). The annual rate of death from cardiovascular causes was 0.52% in the intensive blood pressure control group versus 0.49% in the standard blood pressure control group (P not significant). The annual stroke rate, a prespecified secondary outcome, was 0.32% in the intensive blood pressure control group versus 0.53% in the standard blood pressure control group, P 5 0.01 (number needed to treat to reduce 1 stroke 5 476 patients). Serious adverse events attributed to antihypertensive treatment occurred in 3.3% of the intensive blood pressure control group versus 1.3% of the standard blood pressure control group (P ,0.001) (number needed to treat to increase 1 serious adverse event 5 50 patients). 18 The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial included 9603 diabetic patients, mean age 66.1 years, and 15,981 nondiabetic patients, mean age 66.6 years, with hypertension at high risk for cardiovascular events (Table 1) . 19, 20 A progressive increase in the proportion of visits in which the blood pressure was decreased to ,140/90 mm Hg or to ,130/80 mm Hg was associated with a progressive decrease in stroke, new onset of microalbuminuria or macroalbuminuria, and return to normoalbuminuria in persons with albuminuria. 19 However, the adjusted risk of cardiovascular events was reduced by increasing the frequency of blood pressure control to ,140/90 mm Hg but not to ,130/ 80 mm Hg. 19 The primary outcome in The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Mean follow-up was 4.6 years. Compared with nondiabetic patients, In both diabetic patients and nondiabetic patients, antihypertensive drug treatment reduced the primary outcome if the baseline systolic blood pressure was between 143 to 155 mm Hg. 20 Except for stroke, there was no benefit in reducing fatal or nonfatal cardiovascular outcomes by lowering the systolic blood pressure below 130 mm Hg in diabetic patients and in nondiabetic patients. The lowest incidence of death from cardiovascular causes in diabetic patients occurred with a systolic blood pressure of 135.6 mm Hg (range: 130.6-140.5 mm Hg). The lowest incidence of death from cardiovascular causes in nondiabetic patients occurred with a systolic blood pressure of 133.1 mm Hg (range: 128.8-137.4 mm Hg). For the primary outcome, the highest risk in both diabetic patients and in nondiabetic patients occurred in patients with the lowest or highest in-trial diastolic blood pressure (67.2 mm Hg and 86.7 mm Hg, respectively). 20 The mean systolic blood pressure was 144 mm Hg in both the intensively treated diabetic patients in the United Kingdom Prospective Diabetes Study 27 and in the post hoc subgroup analysis of the Hypertension Optimal Treatment trial. 28 The mean systolic blood pressure was 135 mm Hg in the intensively treated diabetic patients in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation study. 29 Therefore, these 3 studies cannot be used to compare the incidence of cardiovascular events in diabetic patients with hypertension treated to lower the blood pressure to ,140/90 mm Hg versus ,130/80 mm Hg.
A meta-analysis was performed of the 2272 patients with hypertensive chronic kidney disease without diabetes mellitus in the African American Study of Kidney Disease and Hypertension, 21 in the Modification of Diet in Renal Disease, 22 and in the Ramipril Efficacy in Nephropathy 2 23 trials. 24 This meta-analysis (Table 1 ) demonstrated that a blood pressure of ,125/75 to 130/80 mm Hg did not improve clinical outcomes more than a target blood pressure of ,140/90 mm Hg. 24 Whether a blood pressure of ,130/80 mm Hg benefits patients with proteinuria .300 to 1000 mg per day requires further study. 24 The Prevention Regimen for Effectively Avoiding Second Strokes trial included 20,330 patients, mean age 66 years, with a recent non-cardioembolic ischemic stroke (Table 1) . 25 Mean follow-up was 2.5 years.
The primary outcome was first recurrence of stroke of any type. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. The recurrent stroke rates were 8.0% for patients with a systolic blood pressure ,120 mm Hg, 7.2% for patients with a systolic blood pressure of 120-129 mm Hg, 6.8% for patients with a systolic blood pressure of 130-139 mm Hg, 8.7% for patients with a systolic blood pressure of 140-149 mm Hg, and 14.1% for patients with a systolic blood pressure of $150 mm Hg. 25 Compared with patients with a systolic blood pressure of 130-139 mm Hg, the risk of the primary outcome was increased in patients with a systolic blood pressure ,120 mm Hg (adjusted hazard ratio 5 1.29; 95% CI: 1.07-1.56), increased in patients with a systolic blood pressure of 140-149 mm Hg (adjusted hazard ratio 5 1.23; 95% CI: 1.07-1.41), and increased in patients with a systolic blood pressure $150 mm Hg (adjusted hazard ratio 5 2.08; 95% CI: 1.83-2.37). Compared with patients with a systolic blood pressure of 130-139 mm Hg, the risk of the secondary outcome was increased in patients with a systolic blood pressure ,120 mm Hg (adjusted hazard ratio 5 1.31; 95% CI: 1.13-1.52), increased in patients with a systolic blood pressure of 120-129 mm Hg (adjusted hazard ratio 5 1.16; 95% CI: 1.03-1.31), increased in patients increased in patients with a systolic blood pressure of 140-149 mm Hg (adjusted hazard ratio 5 1.24; 95% CI: 1.11-1.39), and increased in patients with a systolic blood pressure $150 mm Hg (adjusted hazard ratio 5 1.94; 95% CI: 1.74-2.16). 25 During more than 12 years of median follow-up in the Cardiovascular Health Study, we found that isolated diastolic hypotension (a diastolic blood pressure ,60 mm Hg with a systolic blood pressure $100 mm Hg) was associated with a 29% independent increase in incident congestive heart failure (P 5 0.003) independent of other cardiovascular risk factors. 30 Therefore, isolated systolic hypertension and isolated diastolic hypotension are significant risk factors for congestive heart failure in community dwelling older persons.
We investigated the impact of baseline systolic blood pressure on outcomes using a propensitymatched design in 7785 patients with mild to moderate chronic systolic and diastolic congestive heart failure in the Digitalis Investigation Group trial (Table 1) . 26 Mean follow-up was 5 years. Compared with a baseline systolic blood pressure .120 mm Hg, a systolic blood pressure of #120 mm Hg was associated with a10% insignificant increase in all-cause mortality, a 15% increase in cardiovascular mortality (P 5 0.031), a 30% increase in heart failure mortality (P 5 0.006), a 13% increase in cardiovascular hospitalization (P 5 0.008), a 10% increase in all-cause hospitalization (P 5 0.017), and a 21% increase in heart failure hospitalization (P 5 0.002). 26 
USE OF ANTIHYPERTENSIVE DRUGS
A meta-analysis of 147 randomized trials including 464,000 persons with hypertension showed that except for the extra protective effect of beta blockers given after myocardial infarction and a minor additional effect of calcium channel blockers in preventing stroke, the use of beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, and calcium channel blockers cause a similar reduction in coronary events and stroke for a given decrease in blood pressure. 8, 31 The proportionate decrease in cardiovascular events was the same or similar regardless of pretreatment blood pressure and the presence or absence of cardiovascular events. 8, 31 Diuretics, ACE inhibitors, ARBs, calcium channel blockers, or beta blockers may be used as initial therapy in the treatment of primary hypertension in older and in younger persons. Atenolol should not be used. [32] [33] [34] Beta blockers such as carvedilol, nebivolol, and bisoprolol are preferred. 34 The American College of Cardiology Foundation/ American Heart Association 2011 expert consensus document on hypertension in the elderly recommended that diuretics, ACE inhibitors, ARBs, beta blockers, and calcium channel blockers have all demonstrated benefit in reducing cardiovascular events in randomized trials. 2 The choice of specific antihypertensive drugs depends on efficacy, tolerability, presence of specific comorbidities, and cost. 2 
CONCLUSIONS
Until additional data from randomized controlled trials (including the Systolic Blood Pressure INtervention Trial) comparing various blood pressure targets in older and younger patients become available, existing epidemiologic and clinical trial data suggest that the blood pressure in patients with hypertension at high risk for cardiovascular events because of coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, or heart failure should be reduced to ,140/90 mm Hg in patients younger than 80 years and the systolic blood pressure reduced to 140-145 mm Hg if tolerated in patients aged 80 years and older.
